Preclinical Safety and Efficacy of TN1008

In the realm of cancer treatment, conventional therapies frequently fall short in achieving complete tumor eradication and preventing recurrence or metastasis in lung cancer patients. A significant contributing factor to these limitations is the presence of cancer stem cells (CSCs). These cells possess the unique ability of self-renewal and play a pivotal role in cancer drug resistance as well as cancer relapse. The focus of this project was the development of novel therapeutic agents designed to specifically target CSCs, aiming to address the challenges posed by these cells in cancer treatment.